EZH2 and Hyperglycemia: Moreover, using an established hyperglycemia model system wherein the EZH2-H3K27me3 pathway is activated, we also showed that targeting this pathway using GSNO reversed endothelial inflammation and monocyte adhesion in diabetic conditions in vitro and ex vivo, which is likely by the S-nitrosylation of EZH2 protein (Fig. 8).